Last reviewed · How we verify

Sofosbuvir-Ribavirin

Ain Shams University · FDA-approved active Small molecule

Sofosbuvir inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, while ribavirin is a nucleoside analog that enhances viral suppression through multiple mechanisms.

Sofosbuvir inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, while ribavirin is a nucleoside analog that enhances viral suppression through multiple mechanisms. Used for Chronic hepatitis C virus (HCV) infection.

At a glance

Generic nameSofosbuvir-Ribavirin
SponsorAin Shams University
Drug classNucleotide polymerase inhibitor + nucleoside analog antiviral
TargetHCV NS5B RNA-dependent RNA polymerase; ribavirin has multiple targets
ModalitySmall molecule
Therapeutic areaVirology / Hepatology
PhaseFDA-approved

Mechanism of action

Sofosbuvir is a nucleotide prodrug that, when activated intracellularly, acts as a chain terminator of HCV RNA synthesis by inhibiting the NS5B polymerase. Ribavirin is a broad-spectrum antiviral nucleoside analog that increases mutation rates in the viral genome and enhances immune responses. Together, this combination directly targets viral replication and has been used historically for HCV treatment, though it has largely been superseded by direct-acting antiviral combinations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: